Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Associated With Better Mortality Than Dipeptidyl Peptidase 4 Inhibitors

April 17, 2018. A network meta-analysis compared the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and dipeptidyl peptidase 4 (DPP-4) inhibitors to reduce all-cause mortality in people with type 2 diabetes (T2D). Included in the meta-analysis were 236 trials with a total of 176,310 participants. GLP-1 RAs and SGLT-2 inhibitors were associated with significantly lower all-cause mortality compared with no treatment or placebo (hazard ratio [HR]: 0.88 and 0.80, respectively) and compared with DPP-4 inhibitors (HR: 0.86 and 0.78, respectively). The investigators concluded that the use of GLP-1 RAs and SLGT-2 inhibitors in patients with T2D is associated with better mortality outcomes than with DPP-4 inhibitors. You can read the study abstract here.